Main Menu
Untitled Page
Home > Equity > Company info > Company Snapshot
21 August 2017

Search Quotes

  Enter at least 3 characters from BSE Code for a company or the company's name

Dr Reddys Laboratories Ltd (Pharmaceuticals - Indian - Bulk Drugs & Formln)

Last Price 1,992.80
Net Changes 10.80
Volume 58144
Prev Close 1,982.00
1,992.80 10.80 (0.54%)
Date: Aug 21,2017 10:04:59




Index Details Pharmaceuticals - Indian - Bulk Drugs & Formln


Chart

Stock Price Details

Market Statistics

Open Price 1982.9 Div Yield (%) 1.02
Buy (Size) 1,990.05(×26) Eps(Rs) 58.36
Sell (Size) 1,991.45(×29) Book Value(Rs) 699.5875332
Buy Quantity 26 Market Cap(Rs.Cr) 32880.59
Sell Quantity 29 Face Value(Rs) 5
Today's High 2001 Market Lot 1
Today's Low 1982.9 AGM Date Jul
52-Week High 3394.95 Book Closure Date Jul
52-Week Low 1901.65 ISIN No. INE089A01023

Share Holding Pattern

  No Of shares % Share Holding
Total Foreign (Promoter & Group) 0 0.00
Indian (Promoter & Group) 44398828 26.78
Total of Promoter 44398828 26.78
Non Promoter (Institution) 71931988 43.38
Non Promoter (Non-Institution) 49471158 29.84
Total Non Promoter 121403146 73.22
Total Promoter & Non Promoter 165801974 100.00
Custodians(Against Depository Receipts) 0 0.00
Grand Total 165801974 100.00

Company News

10-Aug-2017  Dr Reddys Laboratories does not get renewal of GMP compliance...
Dr Reddys Laboratories does not get renewal of GMP compliance certificate

Dr Reddys Laboratories announced that its wholly owned subsidiary, betapharm Arzneimittel GmbH, Germany received a communication from the Regulatory Authority of Germany (Regierung von Oberbayern) last night, that the GMP compliance certificate in respect of the Company's Formulations Manufacturing Unit 2 plant in Bachupally, Hyderabad is not renewed consequent to the recent inspection of the plant. Pending revocation of the non-compliance notification, the plant will not be able to make any further despatch to the European Union until the next inspection, to be initiated by an invitation from betapharm.
10-Aug-2017  Other announcement of Dr. Reddy's Laboratories Ltd
Other announcement of Dr. Reddy's Laboratories Ltd

betapharm Arzneimittel GmbH, Germany (our wholly-owned subsidiary) received a communication from the Regulatory Authority of Germany (Regierung von Oberbayern) last night, that the GMP compliance certificate in respect of the Company's Formulations Manufacturing Unit 2 plant in Bachupally, Hyderabad is not renewed consequent to the recent inspection of the plant. Pending revocation of the non-compliance notification, the plant will not be able to make any further despatch to the European Union until the next inspection, to be initiated by an invitation from betapharm. This is for your information and record.
10-Aug-2017  Dr. Reddy's Laboratories Limited - Updates
Dr. Reddy's Laboratories Limited - Updates

Dr. Reddy's Laboratories Limited has informed the Exchange that Intimation regarding betapharm Arzneimittel GmbH, Germany (our wholly-owned subsidiary) .
09-Aug-2017  Dr. Reddy's Laboratories Limited - Press Release
Dr. Reddy's Laboratories Limited - Press Release

Dr. Reddy's Laboratories Limited has informed the Exchange regarding a press release dated August 09, 2017, titled 'Form 6-K for the quarter ended June 30, 2017, filed with United States Securities Exchange Commission'.
01-Aug-2017  Dr. Reddy's Laboratories Limited - Shareholders meeting
Dr. Reddy's Laboratories Limited - Shareholders meeting

Dr. Reddy's Laboratories Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on July 28, 2017. Further, the company has submitted the Exchange a copy of Srutinizers report along with voting results.
31-Jul-2017  Dr. Reddy's Laboratories Limited - Shareholders meeting
Dr. Reddy's Laboratories Limited - Shareholders meeting

Dr. Reddy's Laboratories Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on July 28, 2017. Further, the company has submitted the Exchange a copy of Srutinizers report along with voting results.
28-Jul-2017  Dr Reddy's extends slide after announcing weak Q1 results
Dr Reddy's extends slide after announcing weak Q1 results

Meanwhile, the S&P BSE Sensex was down 160.21 points or 0.49% at 32,220.87.

Higher than usual volumes were witnessed on the counter. On the BSE, 87,960 shares were traded on the counter so far as against the average daily volumes of 33,530 shares in the past one quarter. The stock had hit a high of Rs 2,530 and a low of Rs 2,465 so far during the day. The stock had hit a 52-week high of Rs 3,394.95 on 28 October 2016 and a 52-week low of Rs 2,382.05 on 29 May 2017.

The stock had underperformed the market over the past one month till 27 July 2017, sliding 1.24% compared with 4.6% rise in the Sensex. The scrip had also underperformed the market in past one quarter, rising 1.09% as against Sensex's 7.84% rise. The scrip had also underperformed the market in past one year, falling 12.28% as against Sensex's 15.55% rise.

The large-cap company has equity capital of Rs 82.91 crore. Face value per share is Rs 5.

Dr Reddy's Laboratories' consolidated net profit declined 56.61% to Rs 66.60 crore on 2.5% rise in net sales to Rs 3315.90 crore in Q1 June 2017 over Q1 June 2016. The result was announced during market hours yesterday, 27 July 2017. The stock had dropped 3.29% to Rs 2,621.45 yesterday, 27 July 2017 post announcement of results.

Dr Reddy's Laboratories' consolidated earnings before interest, taxation, depreciation and amortization (EBITDA) declined 15.56% to Rs 336 crore in Q1 June 2017 over Q1 June 2016. EBITDA margin contracted to 10.1% in Q1 June 2017, from 12.3% in Q1 June 2016.

Meanwhile, Dr Reddy's Laboratories and CHD Bioscience Inc., a privately-held biopharmaceutical company, announced a global licensing agreement for the clinical development and commercialization of Dr Reddy's phase III clinical trial candidate, DFA-02. The announcement was made after market hours yesterday, 27 July 2017.

It is intended to be used for the prevention of surgical site infections, following non-emergency, elective colorectal surgery. Phase II studies for DFA-02 have been successfully completed, and the product will be transitioning to pivotal Phase III registration studies.

Under the terms of the agreement, Dr Reddy's would receive equity in CHD valued at $30 million upon an initial public offer (IPO) of CHD or a minimum of $30 million in cash within 18 months of execution of the agreement. Dr Reddy's will also receive additional milestone payments of $40 million upon US drug regulator's approval. In addition, CHD will pay Dr Reddy's double-digit royalties on sales and commercial milestones.

Dr Reddy's Laboratories is an integrated global pharmaceutical company.

28-Jul-2017  Other announcement of Dr. Reddy's Laboratories Ltd
Other announcement of Dr. Reddy's Laboratories Ltd

Outcome of 33rd Annual General Meeting & Voting results
28-Jul-2017  Dr. Reddy's Laboratories Limited - Press Release
Dr. Reddy's Laboratories Limited - Press Release

Dr. Reddy's Laboratories Limited has informed the Exchange regarding a press release dated July 27, 2017, titled 'Please find enclosed a Press Release on Dr. Reddy s and CHD Bioscience Announce Global License and Commercialization Agreement for Phase III Clinical Trial Candidate for Mitigation of Surgical Site Infections .'.
27-Jul-2017  Dr Reddy's Laboratories consolidated net profit declines 56.61...
Dr Reddy's Laboratories consolidated net profit declines 56.61% in the June 2017 quarter

Net profit of Dr Reddy's Laboratories declined 56.61% to Rs 66.60 crore in the quarter ended June 2017 as against Rs 153.50 crore during the previous quarter ended June 2016. Sales rose 2.52% to Rs 3315.90 crore in the quarter ended June 2017 as against Rs 3234.50 crore during the previous quarter ended June 2016.

ParticularsQuarter Ended
 Jun. 2017Jun. 2016% Var.
Sales3315.903234.50 3
OPM %9.7512.06 -
PBDT339.70442.40 -23
PBT80.50198.80 -60
NP66.60153.50 -57
Incorporation Year 1984 
Registered Office 8-2-337 Road No 3,Banjara Hills,
Hyderabad,
Telangana-500034
Telephone 91-40-49002900 
Fax 91-40-49002999 
Chairman Satish Reddy
Managing Director NA
Company Secretary Sandeep Poddar 
Auditor S R Batliboi & Associates LLP 
Face Value(Rs)
Market Lot
Listing MCX-SX,BSE,New York,NSE 
Registrar Big Share Services Pvt Ltd
3rd Flr 306 Rightwin,Amrutha Ville,Somajiguda,Hyderabad-500082 
Toll Free number: 1800-425-5501 / 1800-103-5501
FINANCIAL TOOLS